Skip to content
Study details
Enrolling now

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

Gagan Joshi
NCT IDNCT06853665ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

196

Study length

about 4 years

Ages

8–18

Locations

1 site in MA

About this study

Researchers are testing a treatment called Adderall XR (mixed salts amphetamine) to see if it helps people with ADHD and autism. The trial will last 1461 days, involving brain imaging scans at MIT. Participants will take either Adderall XR or a placebo for 10 weeks, completing questionnaires and virtual visits.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Adderall XR (mixed salts amphetamine)
  • 2.Take Placebo
PhasePhase 4
DrugAdderall XR (mixed salts amphetamine)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

stimulant (Amphetamine/dextroamphetamine (CNS stimulant combination)), NERVOUS SYSTEM

Endpoints

Secondary: Pre and post treatment changes in ASD core symptoms on Social Responsiveness Scale 2 (SRS-2)

Body systems

Psychiatry / Mental Health